Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2016 1
2017 1
2018 1
2019 1
2020 2
2021 4
2022 2
2023 2
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

15 results

Results by year

Filters applied: . Clear all
Page 1
Immune response characterization in a human challenge study with a Shigella flexneri 2a bioconjugate vaccine.
Clarkson KA, Talaat KR, Alaimo C, Martin P, Bourgeois AL, Dreyer A, Porter CK, Chakraborty S, Brubaker J, Elwood D, Frölich R, DeNearing B, Weerts HP, Feijoo B, Halpern J, Sack D, Riddle MS, Fonck VG, Kaminski RW. Clarkson KA, et al. EBioMedicine. 2021 Apr;66:103308. doi: 10.1016/j.ebiom.2021.103308. Epub 2021 Apr 1. EBioMedicine. 2021. PMID: 33813141 Free PMC article.
Human challenge study with a Shigella bioconjugate vaccine: Analyses of clinical efficacy and correlate of protection.
Talaat KR, Alaimo C, Martin P, Bourgeois AL, Dreyer AM, Kaminski RW, Porter CK, Chakraborty S, Clarkson KA, Brubaker J, Elwood D, Frölich R, DeNearing B, Weerts H, Feijoo BL, Halpern J, Sack D, Riddle MS, Fonck VG. Talaat KR, et al. Among authors: clarkson ka. EBioMedicine. 2021 Apr;66:103310. doi: 10.1016/j.ebiom.2021.103310. Epub 2021 Apr 13. EBioMedicine. 2021. PMID: 33862589 Free PMC article. Clinical Trial.
GMP manufacture of Shigella flexneri 2a Artificial Invaplex (InvaplexAR) and evaluation in a Phase 1 Open-label, dose escalating study administered intranasally to healthy, adult volunteers.
Duplessis C, Clarkson KA, Ross Turbyfill K, Alcala AN, Gutierrez R, Riddle MS, Lee T, Paolino K, Weerts HP, Lynen A, Oaks EV, Porter CK, Kaminski R. Duplessis C, et al. Among authors: clarkson ka. Vaccine. 2023 Oct 6;41(42):6261-6271. doi: 10.1016/j.vaccine.2023.08.051. Epub 2023 Sep 2. Vaccine. 2023. PMID: 37666695 Free article.
Efficacy, safety, and immunogenicity of the Shigella sonnei 1790GAHB GMMA candidate vaccine: Results from a phase 2b randomized, placebo-controlled challenge study in adults.
Frenck RW Jr, Conti V, Ferruzzi P, Ndiaye AGW, Parker S, McNeal MM, Dickey M, Granada JP, Cilio GL, De Ryck I, Necchi F, Suvarnapunya AE, Rossi O, Acquaviva A, Chandrasekaran L, Clarkson KA, Auerbach J, Marchetti E, Kaminski RW, Micoli F, Rappuoli R, Saul A, Martin LB, Podda A. Frenck RW Jr, et al. Among authors: clarkson ka. EClinicalMedicine. 2021 Aug 13;39:101076. doi: 10.1016/j.eclinm.2021.101076. eCollection 2021 Sep. EClinicalMedicine. 2021. PMID: 34430837 Free PMC article.
15 results